RICT 2013<br />Drug Discovery and Selection
Conferences > Archives > RICT 2013
Wednesday July 3, 2013
10:00Registration
11:30Reaxys Workshop: Making Drug Development Easier – Reaxys Medicinal Chemistry
14:00Introductive remarks
Dr Maria DUCA (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Dr Stéphane AZOULAY (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Frédérique VIDAL (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Hans Ulrich STILZ (NOVO NORDISK, Malov, Denmark)
Dr Pascal GEORGE (SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

Session 1: Paul Ehrlich Prize Lecture - Sponsored by Janssen-Cilag

Session Chairmen
Prof. André TARTAR (UNIVERSITY LILLE 2, Lille, France)
Dr Sandrine VENDEVILLE (JANSSEN INFECTIOUS DISEASES, Beerse, Belgium)
14:15Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases
Prof. Michel LAZDUNSKI
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France)

Session 2: Ion Channels

Session Chairman
Prof. Claudiu SUPURAN
(UNIVERSITY OF FIRENZE, Sesto Fiorentino, Italy)
15:15Ion Channel Drug Discovery: a Medicinal Chemistry Perspective
Dr Robert OWEN
(PFIZER NEUSENTIS, Cambridge, United Kingdom)
16:00Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1)
Dr Hartmut SCHIROK
(BAYER, Wuppertal, Germany)
16:45Coffee Break and Exhibition

Session 3: Synergies between Medicinal Chemistry and Biotechnology
Sponsored by Pierre Fabre Research Institute

Session Chairman
Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)
17:45Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives
Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)
18:30Welcome Reception
Thursday July 4, 2013
Session 4:
Case Studies, Immunology & Inflammation
Session 5:
Fragment-Based Drug Design
Session Chairman
Dr Gordon TANG
(ROCHE, Shanghai, China)
08:45GLPG0974, a FFA2 Antagonist from Hit to Clinic
Dr Laurent SANIERE
(GALAPAGOS, Romainville, France)
09:30Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors
Dr Wolfgang HAAP
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
Session Chairman
Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France)
08:45Fragment Screening and Drug Design with Fluorine NMR Spectroscopy
Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)
09:30All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery
Dr James MURRAY
(VERNALIS, Cambridge, United Kingdom)
10:15Coffee Break, Poster Session and Exhibition
Session 6: DruggabilitySession 7: ChemoGenomic
Session Chairman
Dr Luc VAN HIJFTE
(SCT & NOVALIX, Nijmegen, The Netherlands)
10:45Improving Compound Quality in Medicinal Chemistry
Dr Paul LEESON
(ASTRAZENECA, Nuneaton, United Kingdom)
11:30ADMET Modelling: Where is it Worth the Effort?
Dr Richard LAW
(EVOTEC, Abingdon, United Kingdom)
Session Chairman
Dr Paola ARIMONDO
(CNRS - PIERRE FABRE, Toulouse, France)
10:45High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform
Dr Stephen HELLIWELL
(NOVARTIS, Basel, Switzerland)
11:30The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome
Dr Jack BROWN
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom)
12:15Lunch, Poster Session and Exhibition
14:00Career Session
Session 8: Molecular Networks
Session Chairman
Prof. Hans Ulrich STILZ
(NOVO NORDISK, Malov, Denmark)
14:15Molecular Networks : Drug Action and Genome-Informed Medicine
Prof. Giulio SUPERTI-FURGA
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria)
Session 9: Case Studies, Anti-Infective Agents 1Session 10: ChemBioTools
Session Chairman
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
15:00Natural Products as Leads for Drug Discovery
Prof. Karl-Heinz ALTMANN
(ETH ZURICH, Zurich, Switzerland)
15:45Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria
Dr Jean-Philippe SURIVET
(ACTELION, Allschwil, Switzerland)
Session Chairman
Dr Aline MOULIN
(FLAMEL TECHNOLOGIES, Vénissieux, France)
15:00Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases
Dr May MORRIS
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France)
15:45Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans
Prof. David BONNAFFÉ
(UNIVERSITY PARIS-SUD, Orsay, France)
16:30Coffee Break, Poster Session and Exhibition
Session 11: Case Studies: Anti-Infective Agents 2
Sponsored by GlaxoSmithKline
Session 12: GPCR
Session Chairman
Dr Alexis DENIS
(GSK, Courtaboeuf, France)
17:00Validation of Protein Kinases as Drug Targets in the African Trypanosome
Prof. Jeremy MOTTRAM
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)
17:45Drug Discovery for Diseases of the Developing World
Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)
Session Chairman
Dr Stephan SCHANN
(DOMAIN THERAPEUTICS, Strasbourg, France)
17:00Structure and Fragment Based Drug Design for G Protein-Coupled Receptors
Dr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom)
17:45Allosteric Modulation of the Chemokine Receptor CXCR3
Dr Nuska TSCHAMMER
(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany)
20:00Symposium Banquet
Friday July 5, 2013

Session 13: Breaking News

Session Chairman
Dr Frédéric DOLLE
(CEA, SERVICE HOSPITALIER FRÉDÉRIC JOLIOT, Orsay, France)
08:30Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety
Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)
09:15SOM230: A New Therapeutic Modality for Cushing’s Disease
Dr Ian LEWIS
(NOVARTIS, Basel, Switzerland)
10:00Coffee Break, Poster Session and Exhibition

Session 14: Antibody Drug Conjugates
Sponsored by Pierre Fabre Research Institute

Session Chairman
Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)
10:30Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy
Dr Ravi CHARI
(IMMUNOGEN, Waltham, United States)
11:15Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics
Dr Jagath Reddy JUNUTULA
(GENENTECH, South San Francisco, United States)

Session 15: European Lead Factory
Sponsored by ELF Chemistry SMEs : Edelris, Mercachem, Sygnature, Syncom, Taros

Session Chairman
Prof. Joachim MITTENDORF
(BAYER PHARMA AG, Wuppertal, Germany)
12:00The European Lead Factory - A Novel Discovery Partnership Model
Dr Jörg HUESER
(BAYER PHARMA, Wupperthal, Germany)
12:35Lunch, Poster Session and Exhibition

Session 16: Case Studies, Pain & Cancer

Session Chairman
Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)
14:05DAAO Inhibitors as Clinical Candidates
Dr Michele HEFFERNAN
(SUNOVION PHARMACEUTICALS, Marlborough, United States)
14:50How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway
Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)
15:25Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers
Dr Frank HALLEY
(SANOFI, Vitry-sur-Seine, France)
16:10Poster Prizes and Conclusive Remarks
Prof. Janos SAPI
(SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France)

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys